Ash 2025 Congress Coverage Phase Iii Clinical Trials In Aml Catch up with our live social media coverage of the latest developments from early phase clinical trials in acute myeloid leukemia from the 67th american society of hematology (ash) annual meeting and exposition, december 6–9, 2025, orlando, us. The following summaries highlight key findings from research posters presented at the 67th ash annual meeting, showcasing new developments in oral maintenance therapies for acute myeloid leukemia (aml).
Ash Hematology Review Series Aml Sallman D 6 2022 Pdf The ash 2025 dataset builds on the promising efficacy signals previously shared at asco 1 2025, highlighting rapid, deep, and durable responses with a favorable safety profile and encouraging early overall survival. Cullinan therapeutics’ t cell engager, cln 049, has been proven tolerable and safe in an early stage study in relapsed or refractory acute myeloid leukaemia (r r aml) and myelodysplastic syndrome (mds). Researchers from mass general brigham cancer institute will present research discoveries and outcomes from clinical trials at the 2025 american society of hematology (ash) annual meeting, held december 6 9, 2025, in orlando. Experts reflect on pivotal data from the 2025 ash annual meeting that are set to change practice in aml, mzl, fl, and multiple myeloma.
Ash 2025 Annual Meeting Researchers from mass general brigham cancer institute will present research discoveries and outcomes from clinical trials at the 2025 american society of hematology (ash) annual meeting, held december 6 9, 2025, in orlando. Experts reflect on pivotal data from the 2025 ash annual meeting that are set to change practice in aml, mzl, fl, and multiple myeloma. Orlando — azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia compared with induction chemotherapy, according to data. At the american society of hematology’s 67th annual meeting in orlando dec. 6, researcher jesse tettero presented data supporting the use of a measurable residual disease (mrd) surrogate endpoint in acute myeloid leukemia (aml) research. Explore expert presentations & discussions from the post ash 2025 aml webinar hosted by vjhemonc, covering key acute myeloid leukemia updates. Drawing from 10 prospective ecog acrin trials that evaluated intensive chemotherapy for nearly 4000 patients with newly diagnosed aml across nearly four decades, it confirms previously documented racial disparities in black aml patients.
Ash 2025 Annual Meeting Orlando — azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia compared with induction chemotherapy, according to data. At the american society of hematology’s 67th annual meeting in orlando dec. 6, researcher jesse tettero presented data supporting the use of a measurable residual disease (mrd) surrogate endpoint in acute myeloid leukemia (aml) research. Explore expert presentations & discussions from the post ash 2025 aml webinar hosted by vjhemonc, covering key acute myeloid leukemia updates. Drawing from 10 prospective ecog acrin trials that evaluated intensive chemotherapy for nearly 4000 patients with newly diagnosed aml across nearly four decades, it confirms previously documented racial disparities in black aml patients.
Issues 2025 Ash Clinical News American Society Of Hematology Explore expert presentations & discussions from the post ash 2025 aml webinar hosted by vjhemonc, covering key acute myeloid leukemia updates. Drawing from 10 prospective ecog acrin trials that evaluated intensive chemotherapy for nearly 4000 patients with newly diagnosed aml across nearly four decades, it confirms previously documented racial disparities in black aml patients.
Comments are closed.